20 completed, 1 recruiting, 1 terminated, 1 unknown. 9 Phase 2, 9 Phase 3, 3 Phase 1, 1 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 9 | Completed 8, Unknown 1 |
| Phase 3 | 9 | Completed 8, Unknown 1 |
| Phase 1 | 3 | Completed 3 |
| Phase 4 | 1 | Completed 1 |
Follow Extensively Drug-Resistant Tuberculosis: new trials by email Literature Review of Extensively Drug-Resistant Tuberculosis trials Research Report on Extensively Drug-Resistant Tuberculosis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Triage Test for All Oral DR-TB Regimen (TRiAD Study) Xpert® MTB/XDR - Drug Resistant Tuberculosis, MDR-TB | Completed | Centre for the AIDS Programme of Research in South Africa | 786 | 2022-05-26 | 2025-06-26 | |
| A Trial to Evaluate the Male Reproductive Safety of Pretomanid in Adult Male Participants With Drug Resistant Pulmonary Tuberculosis Pretomanid, Bedaquiline, moxifloxacin - Tuberculosis, Pulmonary, Tuberculosis, Multidrug-Resistant | Phase 2 | Completed | Global Alliance for TB Drug Development | 26 | 2021-09-16 | 2025-01-17 |
| Economic Evaluation of New MDR TB Regimens Bedaquiline, Pretomanid, Moxifloxacin - Multi-drug Resistant Tuberculosis, Extensively Drug-Resistant Tuberculosis | Phase 2 / Phase 3 | Completed | Medecins Sans Frontieres, Netherlands | 73 | 2020-10-20 | 2024-04-22 |
| Evaluating Newly Approved Drugs in Combination Regimens for Multidrug-Resistant TB With Fluoroquinolone Resistance (endTB-Q) Bedaquiline 100 MG, Delamanid 50 MG Oral Tablet, Clofazimine 100 MG Oral Capsule - Tuberculosis, Multidrug-Resistant, Tuberculosis | Phase 3 | Completed | Médecins Sans Frontières, France | 323 | 2020-04-06 | 2025-02-10 |
| Case Control Study of Vitamin D Status and Adult Multidrug-resistant Pulmonary Tuberculosis in Maharashtra, India Serum Vitamin D - Multi-drug Resistant Tuberculosis | Completed | Harvard School of Public Health (HSPH) | 352 | 2020-01-27 | 2021-02-25 | |
| Single-dose Study in Two Panels of Healthy Adult Participants to Assess Immediate-Release and Dispersible Formulations of Pretomanid Pretomanid - Multi-drug Resistant Tuberculosis | Phase 1 | Completed | Global Alliance for TB Drug Development | 48 | 2020-01-14 | 2024-07-24 |
| Building Evidence for Advancing New Treatment for Rifampicin Resistant Tuberculosis (RR-TB) Comparing a Short Course of Treatment (Containing Bedaquiline, Delamanid and Linezolid) With the Current South African Standard of Care Bedaquiline Oral Tablet, Linezolid Oral Tablet, Delamanid in Oral Dosage Form - Tuberculosis, Pre-XDR-TB | Phase 3 | Completed | Wits Health Consortium (Pty) Ltd | 402 | 2019-08-22 | 2024-08-28 |
| PRACTECAL-PKPD Sub Study Bedaquiline, Pretomanid, Moxifloxacin - Multi-drug Resistant Tuberculosis, Extensively Drug-Resistant Tuberculosis | Phase 2 / Phase 3 | Unknown | Medecins Sans Frontieres, Netherlands | 240 | 2019-08-06 | 2021-05-14 |
| Safety, Tolerability, Pharmacokinetics and Food Effects Study of PBTZ169 PBTZ169 640 mg OD, PBTZ169 640 mg BiD, PBTZ169 960 mg SD - Healthy Subjects | Phase 1 | Completed | Nearmedic Plus LLC | 60 | 2018-07-03 | 2020-02-28 |
| Various Doses and Durations of Linezolid Plus Bedaquiline & Pretomanid in Participants With Drug Resistant Tuberculosis Pretomanid, Linezolid, Bedaquiline - Tuberculosis, Pulmonary, Tuberculosis, Multidrug-Resistant | Phase 3 | Completed | Global Alliance for TB Drug Development | 181 | 2017-11-21 | 2023-06-29 |
| Pragmatic Clinical Trial for a More Effective Concise and Less Toxic MDR-TB Treatment Regimen(s) Bedaquiline, Pretomanid, Moxifloxacin - Tuberculosis, Multidrug-Resistant, Extensively Drug-Resistant Tuberculosis | Phase 2 / Phase 3 | Completed | Medecins Sans Frontieres, Netherlands | 552 | 2017-01-01 | 2024-05-01 |
| An Open-label RCT to Evaluate a New Treatment Regimen for Patients With Multi-drug Resistant Tuberculosis Linezolid, Bedaquiline, Levofloxacin - Tuberculosis, Multidrug Resistant Tuberculosis | Phase 2 / Phase 3 | Completed | University of Cape Town | 154 | 2015-11-12 | 2021-09-29 |
| A Phase 3 Trial Assessing Safety and Efficacy of B-Pa-L in Participants With DR-TB Bedaquiline, PA-824, Linezolid - Pulmonary Tuberculosis | Phase 3 | Completed | Global Alliance for TB Drug Development | 109 | 2015-03-01 | 2025-09-08 |
| Global Consortium for Drug-resistant Tuberculosis Diagnostics Tuberculosis, Tuberculosis, Multidrug-Resistant | Completed | University of California, San Diego | 1128 | 2012-04-01 | 2014-06-23 | |
| Drug Interaction Study Between Linezolid and Clarithromycin in Tuberculosis Patients Addition of different doses of clarithromycin. - Multidrug-resistant Tuberculosis, Extensively Drug-resistant Tuberculosis | Phase 4 | Completed | University Medical Center Groningen | 7 | 2011-12-01 | 2013-07-01 |
| Training Protocol on the Natural History of Tuberculosis Mycobacterium Infections, Tuberculosis, Multidrug-Resistant | Recruiting | National Institute of Allergy and Infectious Diseases (NIAID) | 150 | 2011-06-30 | 2026-11-10 | |
| Utility of MODS for Diagnosis of MDR-TB and Second-Line Antituberculous Drug Susceptibility Testing in Mali Tuberculosis, Pulmonary, Mycobacterium Tuberculous | Terminated | National Institute of Allergy and Infectious Diseases (NIAID) | 34 | 2011-05-31 | 2018-04-05 | |
| Tuberculosis in China Tuberculosis, Tuberculosis, Multidrug-Resistant | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 199 | 2010-02-02 | 2018-04-05 | |
| Safety and Efficacy of Oral Immunomodulator in Tuberculosis (TB) and TB/HIV Patients V-5 immunitor - Tuberculosis | Phase 2 | Completed | Lisichansk Regional Tuberculosis Dispensary | 123 | 2010-01-01 | 2012-08-03 |
| Adjunct Immunotherapy With Immunoxel in Patients With TB and TB/HIV Immunoxel, Placebo - Tuberculosis, HIV | Phase 3 | Completed | Lisichansk Regional Tuberculosis Dispensary | 269 | 2010-01-01 | 2015-05-20 |
Showing 20 of 23. Sign in to see all of them.
Tuberculosis, Multidrug-Resistant (22) · Tuberculosis (17) · Tuberculosis, Pulmonary (10) · Mycobacterium Infections (3) · Latent Tuberculosis (2) · Anemia (1) · Bacterial Infections (1) · Gram-Positive Bacterial Infections (1) · Optic Nerve Diseases (1) · Peripheral Nervous System Diseases (1) · Thrombocytopenia (1) · Tuberculosis, Extrapulmonary (1) · Vitamin D Deficiency (1)
Actinomycetales Infections (23) · Bacterial Infections and Mycoses (23) · Infections (23) · Bacterial Infections (22) · Gram-Positive Bacterial Infections (22) · Mycobacterium Infections (20) · Lung Diseases (10) · Respiratory Tract Diseases (10) · Respiratory Tract Infections (10) · Tuberculosis (6) · Latent Infection (2) · Avitaminosis (1) · Blood Platelet Disorders (1) · Cranial Nerve Diseases (1) · Cytopenia (1)
Linezolid (10) · bedaquiline (9) · pretomanid (7) · Clofazimine (5) · Moxifloxacin (5) · OPC-67683 (3) · Levofloxacin (2) · Pyrazinamide (2) · BID protein, human (1) · Clarithromycin (1) · Diet (1) · Dosage Forms (1) · Ethionamide (1) · Isoniazid (1) · Kanamycin (1)
Global Alliance for TB Drug Development (4) · National Institute of Allergy and Infectious Diseases (NIAID) (4) · Medecins Sans Frontieres, Netherlands (3) · Lisichansk Regional Tuberculosis Dispensary (2) · Centers for Disease Control and Prevention (1) · Centre for the AIDS Programme of Research in South Africa (1) · Harvard School of Public Health (HSPH) (1) · Médecins Sans Frontières, France (1) · Nearmedic Plus LLC (1) · Otsuka Pharmaceutical Development & Commercialization, Inc. (1) · University Medical Center Groningen (1) · University of California, San Diego (1) · University of Cape Town (1) · Wits Health Consortium (Pty) Ltd (1)
South Africa (11) · United States (4) · Belarus (3) · India (3) · China (2) · Georgia (2) · Moldova (2) · Peru (2) · Russia (2) · South Korea (2) · Ukraine (2) · Uzbekistan (2) · Egypt (1) · Estonia (1) · Ethiopia (1)
Antonio Lombardi, MD (2) · Antonino Catanzaro, MD (1) · Bern Nyang'wa, MB BS, MPH (1) · Bern-Thomas Nyang'wa, MD (1) · Carole Mitnick, Sc.D (1) · Clifton Barry, Ph.D. (1) · Clifton E Barry, Ph.D. (1) · Dmytro Butov, MD (1) · Francesca Conradie (1) · Francesca Conradie, MD (1) · Francesca M Conradie (1) · Jan-Willem C Alffenaar, PhD, PharmD (1) · Jussi Saukkonen, MD (1) · Keertan Dheda, MBChB (1)
PMID 27868466, PMID 21182457, PMID 22397570, PMID 22401633, PMID 22670901, PMID 23075177, PMID 23131255, PMID 23520311, PMID 25377177, PMID 27090176, PMID 27576542, PMID 28381434, PMID 28404672, PMID 28424085, PMID 28475735, PMID 29499645, PMID 31932382, PMID 32130813, PMID 33184081, PMID 34489274, PMID 34604901, PMID 35175905, PMID 35698158, PMID 36053506, PMID 36180816, PMID 36546625, PMID 36804834, PMID 37980911, PMID 38037119, PMID 38842323, PMID 39609025, PMID 39618688, PMID 40683298, PMID 41917253, PMID 42270675, PMID 42341301, PMID 42429813
U01AI082229 (1)